A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerChanghoon Yoo, Jenn-Jiang Hwang, Je Hyeong Kim et al.|British Journal of Cancer|2009Cited by 170
576P The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic modelG.T. Kim, Jong Woo Kim, K-Y. Sohn et al.|Annals of Oncology|2020Cited by 0